ID

21540

Descrizione

Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00646204

collegamento

https://clinicaltrials.gov/show/NCT00646204

Keywords

versioni (1)
  1. 26/04/17 26/04/17 -
Caricato su

26 aprile 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Parkinson's Disease NCT00646204

Inglese

Eligibility Parkinson's Disease NCT00646204

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. subjects must be between the ages of 18 and 80 inclusive.
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
2. each subject must meet standard criteria for pd.
Descrizione

Standard criteria for parkinson's disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C0030567
3. all patients on dopaminergic therapy must report benefit. -no other abnormal neurological signs. -no direct or indirect trauma to the nervous system within 3 months preceding the onset of pd. -no convincing evidence of sudden onset or evidence of stepwise deterioration.
Descrizione

Benefit from dopaminergic therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013036
UMLS CUI [1,2]
C0814225
4. subjects must be in generally good health as evidenced by previous medical history and clinical examination.
Descrizione

Health Status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0018759
5. subjects will be allowed to take any pd medication with the exception of amantadine. they will also be allowed to take medications approved for the use of alzheimer's disease.
Descrizione

Pharmacotherapy for Parkinson except amantadine; pharmacotherapy for alzheimer's disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013216
UMLS CUI [1,2]
C0030567
UMLS CUI [1,3]
C0332300
UMLS CUI [1,4]
C0002403
UMLS CUI [2,1]
C0013216
UMLS CUI [2,2]
C0002395
6. subjects will be required to be on a stable dose of all medications for at least two weeks prior to entry into the study and may not alter these medications throughout the study.
Descrizione

Stable dosage

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0205360
UMLS CUI [1,2]
C0178602
7. if subjects are on an anti-depressant medications, a stable dose of these will be required for at least six weeks prior to entry into the study.
Descrizione

Antidepressant medication

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0003289
8. subjects must be accessible by telephone.
Descrizione

Telephone

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1515258
9. if the subject is a female of childbearing age, she must have had: a hysterectomy, or tubal ligation, or otherwise be incapable or pregnancy, or have practiced one of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility.
Descrizione

Contraceptive methods

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0700589
10. female of childbearing age must have had a negative urine pregnancy test within one week of study entry. 11. prior to participation in this study, each subject must sign an informed consent.
Descrizione

Pregnancy and Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0021430
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. subjects who do not meet inclusion criteria.
Descrizione

Inclusion Criteria

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1512693
2. subjects who are not able to abstain from alcohol for 24 hours prior to each evaluation.
Descrizione

Substance Use Disorder

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0038586
3. subjects who can not maintain an identical dose of any medicine that may affect pd symptoms or signs during their entire study involvement.
Descrizione

Pharmacotherapy affecting Parkinson's disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013216
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0030567
4. subjects who have exhibited meaningful psychiatric disease not thought to be related to pd. (depression and psychosis typical for pd will not be excluded). 5. subjects who have previously taken memantine.
Descrizione

Mental disorder and Memantine

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0004936
UMLS CUI [2]
C0025242
6. subjects currently taking amantadine. 7. subjects with greater than moderate dementia (mmse<24). 8. subjects with co-morbid disease that in the investigators decision could interfere with treatment with memantine.
Descrizione

Amantadine, MMSE, Comorbidity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0002403
UMLS CUI [2]
C0451306
UMLS CUI [3]
C0009488
Ritorna all'inizio della pagina

Similar models

Eligibility Parkinson's Disease NCT00646204

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. subjects must be between the ages of 18 and 80 inclusive.
boolean
C0001779 (UMLS CUI [1])
Standard criteria for parkinson's disease
Item
2. each subject must meet standard criteria for pd.
boolean
C0243161 (UMLS CUI [1,1])
C0030567 (UMLS CUI [1,2])
Benefit from dopaminergic therapy
Item
3. all patients on dopaminergic therapy must report benefit. -no other abnormal neurological signs. -no direct or indirect trauma to the nervous system within 3 months preceding the onset of pd. -no convincing evidence of sudden onset or evidence of stepwise deterioration.
boolean
C0013036 (UMLS CUI [1,1])
C0814225 (UMLS CUI [1,2])
Health Status
Item
4. subjects must be in generally good health as evidenced by previous medical history and clinical examination.
boolean
C0018759 (UMLS CUI [1])
Pharmacotherapy for Parkinson except amantadine; pharmacotherapy for alzheimer's disease
Item
5. subjects will be allowed to take any pd medication with the exception of amantadine. they will also be allowed to take medications approved for the use of alzheimer's disease.
boolean
C0013216 (UMLS CUI [1,1])
C0030567 (UMLS CUI [1,2])
C0332300 (UMLS CUI [1,3])
C0002403 (UMLS CUI [1,4])
C0013216 (UMLS CUI [2,1])
C0002395 (UMLS CUI [2,2])
Stable dosage
Item
6. subjects will be required to be on a stable dose of all medications for at least two weeks prior to entry into the study and may not alter these medications throughout the study.
boolean
C0205360 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
Antidepressant medication
Item
7. if subjects are on an anti-depressant medications, a stable dose of these will be required for at least six weeks prior to entry into the study.
boolean
C0003289 (UMLS CUI [1])
Telephone
Item
8. subjects must be accessible by telephone.
boolean
C1515258 (UMLS CUI [1])
Contraceptive methods
Item
9. if the subject is a female of childbearing age, she must have had: a hysterectomy, or tubal ligation, or otherwise be incapable or pregnancy, or have practiced one of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility.
boolean
C0700589 (UMLS CUI [1])
Pregnancy and Informed Consent
Item
10. female of childbearing age must have had a negative urine pregnancy test within one week of study entry. 11. prior to participation in this study, each subject must sign an informed consent.
boolean
C0032961 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Inclusion Criteria
Item
1. subjects who do not meet inclusion criteria.
boolean
C1512693 (UMLS CUI [1])
Substance Use Disorder
Item
2. subjects who are not able to abstain from alcohol for 24 hours prior to each evaluation.
boolean
C0038586 (UMLS CUI [1])
Pharmacotherapy affecting Parkinson's disease
Item
3. subjects who can not maintain an identical dose of any medicine that may affect pd symptoms or signs during their entire study involvement.
boolean
C0013216 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0030567 (UMLS CUI [1,3])
Mental disorder and Memantine
Item
4. subjects who have exhibited meaningful psychiatric disease not thought to be related to pd. (depression and psychosis typical for pd will not be excluded). 5. subjects who have previously taken memantine.
boolean
C0004936 (UMLS CUI [1])
C0025242 (UMLS CUI [2])
Amantadine, MMSE, Comorbidity
Item
6. subjects currently taking amantadine. 7. subjects with greater than moderate dementia (mmse<24). 8. subjects with co-morbid disease that in the investigators decision could interfere with treatment with memantine.
boolean
C0002403 (UMLS CUI [1])
C0451306 (UMLS CUI [2])
C0009488 (UMLS CUI [3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial